Coronary Artery Bypass Surgery Articles & Analysis
7 news found
The disease that Villix first targeted is ischemic reperfusion injury that occurs in organ transplant myocardial infarction, coronary artery bypass surgery, and stroke. Myocardial infarction occurs after the patient has undergone stenting. ...
Emmert (German Heart Center and Charite Universitatsmedizin, Berlin Germany) Friday, December 3 at the 7th Annual International Coronary Congress in New York City. The GOAL Study is an independent investigator observational clinical study to assess the role of vascular graft /storage solutions on myocardial protection during coronary artery ...
Company closes additional $22.6 million in new financing Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as adjunctive therapy for patients undergoing coronary artery bypass graft surgery XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the ...
Abel Alexander, Regency Lifesciences CEO, said, "This approval and licensure represents a significant step toward providing this novel treatment to the estimated 60,000 Coronary Artery Bypass Graft Surgeries per year." About CABG and DuraGraft When patients with heart disease undergo CABG surgery, free vein or ...
The development program of Elafin is focused on the late stage development of Elafin in major surgery and early stage development in pulmonary arterial hypertension (PAH). ...
The development program of Elafin is focused on the late stage development of Elafin in major surgery and early stage development in pulmonary arterial hypertension (PAH). ...
About Heartcel Heartcell is an allogeneic cell therapy containing off-the-shelf immunomodulatory progenitor (iMP) cells engineered to regenerate the heart. iMPs are administered during coronary artery bypass graft (CABG) surgery by direct injection around the cardiac scar that is to be regenerated. iMP cells have been designated ...